IP Library Granted Patent US 7,186,518
Granted Patent B2
US 7,186,518 · App. 10/719,868 · Granted Mar 6, 2007

Method and composition useful for determining FK 506

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,186,518
App. No.
10/719,868
Granted
Mar 6, 2007
Kind
B2
Abstract

New derivatives of FK 506 are disclosed. These new derivatives and other derivatives that are useful for determining the levels of FK 506 in a sample are also provided as are assay procedures and kits for use in determining the levels of FK 506 or other macrophilin binding substances in blood, particularly un-extracted blood in the presence of specific binding proteins for FK 506.

Claims (14)

1. A method of determining the presence of a macrophilin-binding pharmaceutical in a sample comprising: adding to the sample a binding competitor of the formula:

to displace the macrophilin-binding pharmaceutical from its immunophilin complexes

wherein R is alkyl, aryl, allyl, each having less than 25 carbons or H, and

R′ is alkyl, aryl, allyl, each having less than 25 carbons or H; adding a receptor that binds to the pharmaceutical but not significantly to the binding competitor; detecting the receptor-pharmaceutical complex and correlating the detection with the amount of the pharmaceutical in the sample.

2. The method of claim 1 wherein the pharmaceutical is rapamycin (sirolimus), everolimus or tacrolimus (FK506).

3. A method of determining the presence of a macrophilin-binding pharmaceutical in a sample comprising: adding to the sample a binding competitor of the formula:

to displace the macrophilin-binding pharmaceutical from its immunophilin complexes

wherein R is alkyl, aryl, allyl, each having less than 25 carbons or H, and

R′ is alkyl, aryl, allyl, each having less than 25 carbons or H; adding a receptor that binds to the pharmaceutical but not significantly to the binding competitor; detecting the receptor-pharmaceutical complex and correlating the detection with the amount of the pharmaceutical in the sample.

4. The method of claim 3 wherein the pharmaceutical is rapamycin (sirolimus), everolimus or tacrolimus (FK506).

5. The method of claim 4 wherein R or R′ is ethyl.

6. The method of claim 2 wherein R or R′ is ethyl.

7. The method of claim 1 wherein R or R′ further comprise at least one functional group selected from the group consisting of esters, ethers, amides, phosphates, sulfonates, sulfate, amidines, phosphonates, amine, hydroxyl or carboxylate functional groups.

8. The method of claim 3 wherein R or R′ further comprise at least one functional group selected from the group consisting of esters, ethers, amides, phosphates, sulfonates, sulfate, amidines, phosphonates, amine, hydroxyl or carboxylate functional groups.

Assignments (4)
MERGER Recorded Mar 25, 2008
From: DADE BEHRING INC.
To: SIEMENS HEALTHCARE DIAGNOSTICS INC.
Reel/Frame 020690/0530 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2005
From: DEUTSCHE BANK AG, NEW YORK BRANCH
To: DADE BEHRING INC.
Reel/Frame 015953/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2004
From: WANG, GHENGRONG; WEI, TIE Q.; TENG, ZHU
To: DADE BEHRING INC.
Reel/Frame 016249/0587 →
SECURITY INTEREST Recorded Aug 16, 2004
From: DADE BEHRING INC.
To: DEUTSCHE BANK AG
Reel/Frame 015062/0832 →